Artal Group S.A. Revolution Medicines, Inc. Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$30.14 - $40.68 $9.13 Million - $12.3 Million	-302,873 Reduced 22.97%	1,015,776 $39.4 Million
Q1 2024 May 13, 2024	SELL	$26.56 - $33.55 $10 Million - $12.7 Million	-377,300 Reduced 22.25%	1,318,649 $42.5 Million
Q4 2023 Feb 09, 2024	SELL	$18.35 - $34.12 $15.3 Million - $28.4 Million	-833,788 Reduced 32.96%	1,695,949 $48.6 Million
Q3 2023 Nov 13, 2023	BUY	$25.17 - $35.05 $3.22 Million - $4.49 Million	128,120 Added 5.33%	2,529,737 $70 Million
Q2 2023 Aug 11, 2023	BUY	$20.28 - $27.0 $6.71 Million - $8.93 Million	330,629 Added 15.96%	2,401,617 $64.2 Million
Q1 2023 May 12, 2023	BUY	$20.76 - $30.09 $22.2 Million - $32.2 Million	1,070,988 Added 107.1%	2,070,988 $44.9 Million
Q4 2022 Feb 13, 2023	BUY	$17.68 - $25.53 $17.7 Million - $25.5 Million	1,000,000 New	1,000,000 $23.8 Million

266

161M

260K

620K

Ticker RVMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,697,600
Market Cap $3.88B
Description
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.